Adalimumab for Long-Term Treatment of Psoriatic Arthritis Forty-Eight Week Data From the Adalimumab Effectiveness in

Objective. To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti–tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA). Methods. Patients who completed the Adali-mumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), a 24-week, double-blind study of adalimumab versus placebo in PsA, could elect to receive open-label adalimumab, 40 mg subcutaneously every other week after week 24. Radiographs were obtained at week 48 and were read with radiographs obtained previously. Clinical and radiographic efficacy data were analyzed overall and in patient subsets. Safety data were collected over 48 weeks